Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial-Reference-Cited by-同舟云学术

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Published:2018-05-19 Issue:8 Volume:61 Page:1712-1723
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Verma Subodh,Mazer C. David,Fitchett David,Inzucchi Silvio E.,Pfarr Egon,George Jyothis T.,Zinman Bernard

Funder

The EMPA-REG OUTCOME trial was funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/article/10.1007/s00125-018-4644-9/fulltext.html

Reference34 articles.

1. Rana JS, Dunning A, Achenbach S et al (2012) Differences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes undergoing coronary computed tomography angiography: results from 10,110 individuals from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes): an InteRnational Multicenter Registry. Diabetes Care 35:1787–1794

2. Verma S, Farkouh ME, Yanagawa B et al (2013) Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 1:317–328

3. Ryden L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087

4. Farkouh ME, Domanski M, Sleeper LA et al (2012) Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367:2375–2384

5. Kappetein AP, Head SJ, Morice MC et al (2013) Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 43:1006–1013

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Euglycemic Diabetic Ketoacidosis with SGLT2 Inhibitor Therapy in a Patient Undergoing Off-Pump Coronary Artery Bypass: A Case Report;Journal of Cardiac Critical Care TSS;2024-06-07

2. Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy;Antioxidants;2024-05-30

3. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

4. Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review;Journal of Diabetes Research;2024-05-11

5. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-04-10